CLAAS System
Phase 3- Indications
- Left atrial appendage occlusion for stroke prevention in atrial fibrillation
Company intelligence / Profile preview
Conformal Medical has developed the CLAAS System, an investigational left atrial appendage occlusion (LAAO) device designed to reduce stroke risk in patients with non-valvular atrial fibrillation without the need for long-term anticoagulants. The system aims to simplify and improve LAA closure procedures by conforming to individual patient anatomy and enabling same-day, single operator procedures. The company holds a robust patent portfolio covering key innovations in implant design and delivery. Clinical trials are ongoing; no commercial results have been reported yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Conformal Medical.